WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 5th levels

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

ATC codeATC level nameDeadline for objection to temporary codesImplementation in ATC/DDD index
A02BC10fexuprazan01.02.20242025
A02BC11Ilaprazole01.02.20242025
A10BD30gemigliptin and dapagliflozin01.02.20242025
A10BK09enavogliflozin01.02.20242025
A10XX02donislecel01.02.20242025
A16AX24govorestat01.02.20242025
B02BD17fidanacogene elaparvovec01.02.20242025
B03XA09molidustat01.02.20242025
B03XA10efepoetin alfa01.02.20242025
B06AC07garadacimab01.02.20242025
C01EB25acoramidis01.02.20242025
C02KX06sotatercept01.02.20242025
C08DA03etripamil01.02.20242025
C09XX01sparsentan01.02.20242025
C10BA13pitavastatin and ezetimibe01.02.20242025
C10BX22rosuvastatin and nebivolol01.02.20242025
J01DF51aztreonam and beta-lactamase inhibitor01.02.20242025
J01RA17ofloxacin and nitazoxanide01.02.20242025
J01RA18ofloxacin and tinidazole01.02.20242025
J01RA19tetracycline and nystatin01.02.20242025
J01XX13gepotidacin01.02.20242025
J04AC02ftivazide01.02.20242025
J04AM09pyrazinamide, ethambutol, isoniazid and lomefloxacin01.02.20242025
J04AM10pyrazinamide, ethambutol, protionamide and lomefloxacin01.02.20242025
J04AM11rifabutin, pyrazinamide and protionamide01.02.20242025
J04AM12rifampicin, pyrazinamide, isoniazid and levofloxacin01.02.20242025
J05AG07elsulfavirine01.02.20242025
J05AP14narlaprevir01.02.20242025
J05AR29emtricitabine, tenofovir alafenamide and dolutegravir01.02.20242025
J05AX32riamilovir01.02.20242025
J06BD09sipavibart01.02.20242025
J07AH11meningococcus A,B,C,Y,W-135, pentavalent purified polysaccharides antigen conjugated and factor H binding protein01.02.20242025
J07BB05influenza, RNA-based vaccine01.02.20242025
L01DC05utidelone01.02.20242025
L01EL06tirabrutinib01.02.20242025
L01EX28repotrectinib01.02.20242025
L01FD07zanidatamab01.02.20242025
L01FX31zolbetuximab01.02.20242025
L01FX32elranatamab01.02.20242025
L01FX33tarlatamab01.02.20242025
L01FX34odronextamab01.02.20242025
L01XH06tucidinostat01.02.20242025
L01XH07resminostat01.02.20242025
L01XM03olutasidenib 01.02.20242025
L01XM04vorasidenib 01.02.20242025
L01XX81nirogacestat01.02.20242025
L04AA60remibrutinib01.02.20242025
L04AC26goflikicept01.02.20242025
L04AG17seniprutug01.02.20242025
L04AJ10vilobelimab01.02.20242025
M01AE19loxoprofen01.02.20242025
N02CD08zavegepant01.02.20242025
N06AX31zuranolone01.02.20242025
N07BB06ondelopran01.02.20242025
N07XX24trofinetide01.02.20242025
P01AB08satranidazole01.02.20242025
P01AB53tinidazole and diloxanide01.02.20242025
S01AX25lotilaner01.02.20242025
S01EA55brimonidine and ripasudil01.02.20242025
S01EE52latanoprost and dorzolamide01.02.20242025
S01XA32avacincaptad pegol01.02.20242025
V04CX12xenon01.02.20242025
V09IX18flotufolastat (18F)01.02.20242025
V10XA04iodine (131I) apamistamab01.02.20242025

Last updated: 2023-12-12